John Kerrigan
Overview
Explore the profile of John Kerrigan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
308
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Piizzi G, Parker D, Peng Y, Dobler M, Patnaik A, Wattanasin S, et al.
J Med Chem
. 2017 May;
60(12):5002-5014.
PMID: 28549219
Over the past several decades, the frequency of antibacterial resistance in hospitals, including multidrug resistance (MDR) and its association with serious infectious diseases, has increased at alarming rates. Pseudomonas aeruginosa...
2.
Bansal N, Bartucci M, Yusuff S, Davis S, Flaherty K, Huselid E, et al.
Clin Cancer Res
. 2016 Jun;
22(24):6176-6191.
PMID: 27307599
Purpose: Current prostate cancer management calls for identifying novel and more effective therapies. Self-renewing tumor-initiating cells (TICs) hold intrinsic therapy resistance and account for tumor relapse and progression. As BMI-1...
3.
Tedeschi P, Scotto K, Kerrigan J, Bertino J
Oncotarget
. 2016 Feb;
7(7):7368-9.
PMID: 26848977
No abstract available.
4.
Tsang Y, Dogruluk T, Tedeschi P, Wardwell-Ozgo J, Lu H, Espitia M, et al.
Nat Commun
. 2016 Jan;
7:10500.
PMID: 26806015
As we enter the era of precision medicine, characterization of cancer genomes will directly influence therapeutic decisions in the clinic. Here we describe a platform enabling functionalization of rare gene...
5.
Bjorklund S, Kristensen V, Seiler M, Kumar S, Grenaker Alnaes G, Ming Y, et al.
BMC Cancer
. 2015 Jul;
15:524.
PMID: 26183823
Background: Alternate transcripts from a single gene locus greatly enhance the combinatorial flexibility of the human transcriptome. Different patterns of exon usage have been observed when comparing normal tissue to...
6.
Kortagere S, Lill M, Kerrigan J
Methods Mol Biol
. 2012 Sep;
929:21-48.
PMID: 23007425
Over the past two decades computational methods have eased up the financial and experimental burden of early drug discovery process. The in silico methods have provided support in terms of...
7.
Lin R, Zhou N, Lyu Y, Tsai Y, Lu C, Kerrigan J, et al.
J Biol Chem
. 2011 Aug;
286(38):33591-600.
PMID: 21828038
Studies in animal models have indicated that dietary isothiocyanates (ITCs) exhibit cancer preventive activities through carcinogen detoxification-dependent and -independent mechanisms. The carcinogen detoxification-independent mechanism of cancer prevention by ITCs has...
8.
Park H, Zheng H, Kulkarni D, Kerrigan J, Pungaliya P, Saleem A, et al.
Biochemistry
. 2008 Dec;
47(52):13887-96.
PMID: 19053840
TOPORS is the first example of a protein that possesses both ubiquitin and SUMO E3 ligase activity. The ubiquitination activity maps to a conserved RING domain in the N-terminal region...
9.
Gani R, Giovannoni G, Bates D, Kemball B, Hughes S, Kerrigan J
Pharmacoeconomics
. 2008 Jun;
26(7):617-27.
PMID: 18563952
Background: Natalizumab (Tysabri) is a new disease-modifying therapy that has been shown to be clinically effective in patients with relapsing-remitting multiple sclerosis (RRMS) and has been licensed for use in...
10.
The distribution of the cost of multiple sclerosis in the UK: how do costs vary by illness severity?
Tyas D, Kerrigan J, Russell N, Nixon R
Value Health
. 2007 Sep;
10(5):386-9.
PMID: 17888103
Objectives: To derive robust estimates for the cost of multiple sclerosis (MS) based on a variety of cost factors across a number of different cost perspectives. This is essential to...